苦参素针剂治疗肝纤维化的临床研究  

Clinical study of oxymatrine on the Iiver fibrosis

作　　者：应文军[1] 高泽立[2] 郑瑜[2] 

机构地区：[1]南京钢铁集团有限公司医院,南京210035 [2]上海第二医科大学附属宝钢医院

出　　处：《胃肠病学和肝病学杂志》2002年第3期237-238,共2页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的　检测苦参素的抗肝纤维化作用。方法　早、中期肝纤维化患者 5 0例 ,肝功能Child分级A、B级 ,随机分为治疗组和对照组。治疗组予苦参素针剂 (KusensuSolution ,KS) ,40 0mg× 90d ,肌肉注射 ,对照组给予一般护肝及对症治疗。检测项目 :肝纤维化指标 :层粘蛋白体 (Laminin ,LN)、透明质酸 (Hyaluronicacid ,HA)、Ⅲ型胶原和Ⅳ型胶原 ;肝功能相关指标 :凝血酶原时间 (PT)、血清白蛋白、胆汁酸 (Totalbileacid ,TBA)。结果　治疗 6个月后 ,治疗组LN、HA、Ⅲ型胶原水平及TBA含量下降 ,与治疗前及对照组比较有显著差异。结论　苦参素可使早、中期肝纤维化患者肝纤维化指标水平下降 ,苦参素做为抗肝纤维化药 ,值得在临床推广使用。Aim To investigate the anti-fibrosis effect of oxymatrine.Methods 50 patients whose liver functions were Child A or B with mild or moderate liver fibrosis were selected.All patients were divided into treatment group (30 cases) and control group (20 cases) at random.Treatment group was given Kusensu Solution (KS) im,400 mg×90 d,while control group only got ordinary liver protective drugs.Liver fibrosis markers such as laminin(LN),hyaluronic acid(HA),collagen type Ⅲ and Ⅳ as well as liver function reflecting items:albumin,total bile acid (TBA),prothrombin time (PT) were tested after treatment.The results were analized with t-test and rank sum test.Results The serum extracellular matrix (ECM):laminin(LM),hyaluronic acid(HA),collagen type Ⅲ reduced significantly compared with those of control group,and the level of total bile acid (TBA) also greatly reduced.Conclusion KS can reduce the ECM in patients with mild and moderate fibrosis,indicating that KS is a promising drug for liver fibrosis.

关 键 词：苦参素针剂 治疗 肝纤维化 临床研究 

分 类 号：R575.2[医药卫生—消化系统]